Search for Clinical Trial Results
Angioimmunoblastic T-cell Lymphoma - 244 Studies Found
Status | Study |
Recruiting |
Study Name: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Condition:
|
Completed |
Study Name: RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Condition:
Interventions: Drug: RAD001 (Everolimus) Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO d |
Recruiting |
Study Name: Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study Condition:
|
Active, not recruiting |
Study Name: Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Condition:
Interventions: Drug: carfilzomib Given IV Other Names: |
Recruiting |
Study Name: Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Condition:
|
Recruiting |
Study Name: VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma Condition:
Interventions: |
Recruiting |
Study Name: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Condition:
|
Recruiting |
Study Name: CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Condition:
|
Recruiting |
Study Name: CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Condition:
|
Terminated |
Study Name: Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Condition:
|